Abstract:Malignant pleural mesothelioma (MPM) is an aggressive rare cancer affecting the pleura and is predominantly associated with prior exposure to asbestos. Treatment options are limited, and most patients die within 24 months of diagnosis. There is an urgent unmet need to identify new therapeutic options for the treatment of MPM. Asbestos fibers contain transition metals such as iron, and may cause an alteration of iron homeostasis in the tissue. In addition, asbestos fibers have also been shown to have high affinity for histones, and therefore may result in high accumulation of iron around chromatin. Lysine Demethylases (KDMs) containing a JmjC domain require both Fe2+ and 2-oxoglutarate as co-factors to regulate gene expression. Bromodomain containing proteins a family of chromatin reader proteins have potential therapeutic efficacy against various malignancies. Long non-coding RNAs (lncRNAs) have also been shown to play a role as oncogenic molecules in different cancers. Several such lncRNAs have now been shown to locate to the same chromosomal region as various KDMs. We therefore examined the expression of various JmjC and Brd members (along with any associated lncRNAs) in MPM and assessed some for their clinical potential using existing small molecule inhibitors. A panel of MPM cell lines and a cohort of snap-frozen patient samples isolated at surgery comprising benign, epithelial, biphasic, and sarcomatoid histologies were screened for expression of various BRD and JmjC members and associated lncRNAs by RT-PCR. IHC for KDM4A was performed on a cohort of FFPE specimens. The effects of treatments with small molecule inhibitors targeting these proteins on both cellular health and gene expression were assessed. The expression of the various KDMs was detectable across our panel of cell lines. In primary tumors the expression of many of these genes were significantly elevated in malignant MPM compared to benign pleura (p<0.05), and significant differences were also observed when samples were analyzed across different histological subtypes. Treatment of mesothelioma cell lines with various small molecule inhibitors caused significant effects on cellular health and on the expression of a panel of genes. The expression of various KDMs, BRD genes and associated lncRNAs are significantly altered in MPM. Small molecule inhibitors directed against these show potential therapeutic efficacy with significant anti-proliferative effects. We continue to assess the effects of these compounds on gene expression and cellular health to confirm their potential utility as novel therapies for the treatment of MPM.

MA06.05 Targeting Anti-Apoptotic Mechanisms in Malignant Pleural Mesothelioma

[Advances in Targeted Therapy for Malignant Pleural Mesothelioma]

Biomarker-guided Targeted and Immunotherapies in Malignant Pleural Mesothelioma

Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma

Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications

Molecular Targeted Therapy of Malignant Pleural Mesothelioma

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment

Therapeutic Targeting of MEK1/2 Synergizes with PARP1 Inhibitors in the Treatment of Malignant Pleural Mesothelioma

Kdm6a and Kdm6b: Altered Expression in Malignant Pleural Mesothelioma

MEK1 Drives Oncogenic Signaling and Interacts with PARP1 for Genomic and Metabolic Homeostasis in Malignant Pleural Mesothelioma.

Research Progress on Molecular Mechanism Underlying Chemotherapy Resistance of Malignant Pleural Mesothelioma

Endoplasmic Reticulum Stress Signaling As A Therapeutic Target In Malignant Pleural Mesothelioma

Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma

MA17.08 Whole-Genome CRISPR Screening Reveals Genetic Vulnerabilities and Therapeutic Targets in Malignant Pleural Mesothelioma

Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets

Malignant pleural mesothelioma co-opts BCL-X L and autophagy to escape apoptosis

P1.09-006 JMJ and BRD Domain Family Members in Malignant Pleural Mesothelioma: Potential Therapeutic Targets or Not?

KAT5 (tip60) is a Potential Therapeutic Target in Malignant Pleural Mesothelioma.

731 EVALUATION OF THE SELF-DESIGNED ULTRASONIC ATOMIZATION SPRAYING EQUIPMENT FOR INTRAVASCULAR STENTS

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma

Molecular Changes in Mesothelioma With an Impact on Prognosis and Treatment